Figure 5
In vivo adjuvant activity elicited by PbCSP antigen with GLA-AF. (a) Antibody endpoint titers measured two weeks after the second immunization. Each group consisted of 4–5 mice immunized with 1 μg GLA-AF and 2 μg PbCSP. Each of the adjuvanted groups achieved statistical significance in IgG2c titers compared to PbCSP alone (p < 0.05). No other statistical differences between groups were apparent. (b) Cytokine ELISAs of splenocytes collected six weeks after the third immunization and stimulated with antigen. Each group consisted of 5 mice immunized with 1 μg GLA-AF and 2 μg PbCSP, with each value consisting of an average of two duplicates. No statistical differences between groups were present. (c) Splenocytes producing cytokines six weeks after the third immunization, detected by ELISPOT assay. Each group consisted of 5 mice immunized with 1 μg GLA-AF and 2 μg PbCSP, with each value consisting of an average of two duplicates. The number of IFNγ-producing cells from the PbCSP + GLA-AF Avanti group acheived statistical significance (p < 0.05) compared to PbCSP alone, PbCSP + GLA-AF NOF, and PbCSP + GLA-AF Lipoid. No other statistical differences between groups were apparent.